Evolus, Inc. (EOLS)
| Market Cap | 477.76M |
| Revenue (ttm) | 58.29M |
| Net Income (ttm) | -136.88M |
| Shares Out | 37.10M |
| EPS (ttm) | -3.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $9.06 |
| Previous Close | $8.66 |
| Change ($) | 0.40 |
| Change (%) | 4.62% |
| Day's Open | 8.72 |
| Day's Range | 8.66 - 9.22 |
| Day's Volume | 946,677 |
| 52-Week Range | 2.85 - 17.38 |
Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact
Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumto...
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
With the trading day about halfway over, the broad markets were somewhat mixed. The Dow Jones industrial average and S&P 500 each posted a handy gain, while the Nasdaq was barely in the red.
NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced ...
Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Few are smiling about the company's upcoming share issue.
NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its public offering of 9,000,000 shares of its common stock at a public offering pric...
NEWPORT BEACH, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other condition...
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -231.82% and -0.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ®
Evolus Inc (NASDAQ: EOLS) has announced that its strategic partner Daewoong Pharmaceutical Co. Ltd will pay Evolus $25.5 million in cash and eliminate $10.5 million of current and potential future miles...
NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announce...
Pro Forma Cash Position of $57 Million at December 31, 2020 1
NEWPORT BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today an...
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...
Evolus (EOLS) stock was on the rise Friday following news that it's no longer dealing with lawsuits from AbbVie (ABBV) and Medytox. The post EOLS Stock: The Big News That Has Evolus Shares Skyrocketing ...
NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ann...
Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechno...
Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (I...
NORTH CHICAGO, Ill. and NEWPORT BEACH, Calif. and SEOUL, Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstand...
Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.
Section 337 Violation Partially Affirmed by ITC
New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. (NASDAQ: EOLS) ("Evolus" ...
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 20...
BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed on beha...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. ("Evolus” or "the Company") (NASDAQ: EOLS) and certain of...
Los Angeles, California--(Newsfile Corp. - December 14, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...
New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019...
Investors with losses in excess of $1,000,000 are encouraged to contact the firm before December 15, 2020; click here to submit trade information Investors with losses in excess of $1,000,000 are encour...
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $250,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $250,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United S...
LOS ANGELES--(BUSINESS WIRE)---- $EOLS #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action fil...
Los Angeles, California--(Newsfile Corp. - December 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...
Los Angeles, California--(Newsfile Corp. - December 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (...
LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 15, 2020 deadline to file a lead plaintiff motion in the class action filed ...
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, has filed a federal securities class action in the United State...
Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...
Los Angeles, California--(Newsfile Corp. - December 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (th...
Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolus, Inc. (NA...
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolus To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - Dec...
New York, New York--(Newsfile Corp. - December 4, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 ...
Investors with losses in excess of $1,000,000 are encouraged to contact the firm before December 15, 2020; click here to submit trade information
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). The class a...
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, i...
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 8, 2018 |
| CEO David Moatazedi | Employees 119 |
| Stock Exchange NASDAQ | Ticker Symbol EOLS |
Financial Performance
In 2020, Evolus's revenue was $56.54 million, an increase of 61.89% compared to the previous year's $34.93 million. Losses were -$163.01 million, 81.1% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for Evolus stock is "Buy." The 12-month stock price forecast is 17.11, which is an increase of 88.85% from the latest price.